Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc. Show more

5005 McConnell Avenue, Los Angeles, CA, 90066, United States

Biotechnology
Healthcare
Start AI Chat

Market Cap

347.3M

52 Wk Range

$0.90 - $16.34

Previous Close

$9.54

Open

$9.85

Volume

149,465

Day Range

$9.68 - $11.90

Enterprise Value

250.8M

Cash

14.76M

Avg Qtr Burn

-4.298M

Insider Ownership

69.12%

Institutional Own.

3.41%

Qtr Updated

09/30/25